Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 62.94B +45.4% |
| Revenue (ttm) | 28.42B +3.1% |
| Net Income | -1.01B |
| EPS | -0.32 |
| Shares Out | 1.58B |
| PE Ratio | n/a |
| Forward PE | 20.62 |
| Dividend | $0.49 (2.50%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 2,718,107 |
| Open | 19.67 |
| Previous Close | 19.45 |
| Day's Range | 19.56 - 19.71 |
| 52-Week Range | 12.99 - 19.89 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 22.77 (+15.76%) |
| Earnings Date | Oct 29, 2026 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
Analyst Summary
According to 3 analysts, the average rating for TAK stock is "Strong Buy." The 12-month stock price target is $22.77, which is an increase of 15.76% from the latest price.
News
Takeda Launches ORZEYFUL For Narcolepsy Type 1 In Japan, China; Stock Up
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T), which explores orexin science, announced on Thursday that ORZEYFUL (oveporexton) is now available in Japan and China to treat Narcolepsy Ty...
Takeda’s ORZEYFUL launches in Japan and China
Takeda (TAK) “announced that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with…
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1...
Takeda's TAK-881 Cuts Infusion Time By 42.6% In Phase 3 PID Study
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), a biopharmaceutical company developing treatments for rare diseases and other conditions, presented detailed Phase 2/3 IgGNITE study results fo...
Takeda announces Phase 2/3 IgGNITE trial met primary endpoint
Takeda (TAK) announced detailed results from the Phase 2/3 IgGNITE clinical trial, TAK-881-3001, evaluating investigational TAK-881, which, if approved, has the potential to become the first facilitat...
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
Takeda (TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib, an investigational, next-generation, highly selective and potent oral tyrosine kinase 2, or TYK2, inhibito...
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib
Takeda (TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib, an investigational, next-generation, highly selective and potent oral tyrosine kinase 2, or TYK2, inhibito...
Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK, 4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasi...
Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis...
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generat...
Keros Therapeutics to receive $20M development milestone payment from Takeda
Keros Therapeutics (KROS) announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda (TAK), following ...
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.
Roche Proposes Former Takeda CEO Christophe Weber For Board Role
(RTTNews) - Roche (RHHBY) announced that its Board of Directors has approved a proposal to nominate Dr. Christophe Weber, the former CEO of Takeda Pharmaceuticals, for election to Roche's Board of Dir...
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Onco...
Takeda Unveils $22.2 Mln CSR Collaborations Focused On Climate-Resilient Health; Stock Up
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK), a commercial-stage pharmaceutical company announced that it has granted $22.2 million to four new Corporate Social Responsibility (CSR) partners t...
Dengue vaccine to hit market by first half of 2027
India News: NEW DELHI: India's first dengue vaccine is expected to be available in the private market in the first half of 2027. Takeda Pharma and Dr Reddy's Labo.
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partner...
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation Officer Lauren Duprey Sells ...
Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation Officer Lauren Duprey Sells 34,535 Shares
Takeda Pharmaceutical Company Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership transition and a new strategic phase are underway, with a focus on deep pipeline investment and upcoming launches like ORZEYFUL and zasocitinib. Key data readouts for TAK-360 and IBD indications are expected by the end of the fiscal year, supporting a steady flow of future launches.
Takeda's Zasocitinib NDA Gets FDA Priority Review For Plaque Psoriasis; PDUFA Date Set For Q1' 27
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), on Monday reported that the U.S. Food and Drug Administration (FDA) has accepted Zasocitinib's New Drug Application (NDA) under priority review...
Takeda announces FDA acceptance of zasocitinib under priority review
Takeda (TAK) announced that the FDA accepted its new drug application, or NDA, under priority review for zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib i...
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review fo...
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
MALMO, Sweden & WILMINGTON, Del.--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place Septem...